Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339039 | 0.91 | KCNH2 (0.58) | KCNH2LMNAKMT2APDE1B | |
| SCHEMBL6349435 | 0.91 | KCNH2 (0.70) | KCNH2LMNAKMT2A | |
| SCHEMBL6660872 | 0.90 | KCNH2 (0.69) | KCNH2NPC1POLB | |
| SCHEMBL6341102 | 0.82 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6706436 | 0.82 | KCNH2 (0.84) | KCNH2KMT2A | |
| SCHEMBL6338143 | 0.81 | KCNH2 (0.82) | KCNH2KMT2A | |
| SCHEMBL6658972 | 0.81 | KCNH2 (0.69) | KCNH2LMNARECQLKMT2A | |
| SCHEMBL6347100 | 0.81 | KCNH2 (0.57) | KCNH2LMNA | |
| SCHEMBL6336388 | 0.81 | KCNH2 (0.56) | KCNH2LMNA | |
| SCHEMBL6346192 | 0.80 | KCNH2 (0.55) | KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | claimed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | claimed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | claimed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | claimed |
| US-6924283-B2 | 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PFIZER (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1421088-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2003-05-29 | — | — | US | disclosed |
| WO-2003020730-A1 | 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100536-A1 | 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents | TPMT, TK1, TYMP | KCNH2 2260/4885LMNA 4637/4885RECQL 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.